Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients This...
-
Top line results from the 172-patient trial to be reported in early 2018Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe14...
-
HAIFA, Israel, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the...
-
Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectivelyGrant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation...
-
HAIFA, Israel, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that following...
-
Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
Pluristem and Sosei CVC will establish a new corporation which will pursue the clinical development and commercialization of PLX-PAD in JapanThe first indication to be developed will be Critical Limb...
-
Pluristem與Sosei CVC將成立一間新公司，這間新公司將會在日本推進PLX-PAD的臨床開發及商品化急性肢體缺血(CLI)將成為首個針對性開發的適應症日本監管機構已同意在快速通道下就潛在的有條件市場推廣審批對75位病人的CLI臨床試驗進行的研究設計Sosei RMF1與合作夥伴將向新公司投入初期資金1,100萬美元 以色列海法及東京, Dec. 21, 2016 (GLOBE...
-
Pluristem与Sosei CVC将成立一家新公司，这家新公司将在日本推进PLX-PAD的临床开发及商品化急性肢体缺血(CLI)将成为首个针对性开发的适应症日本监管机构已同意在快速通道下就潜在的有条件市场推广审批对75位病人的CLI临床试验进行的研究设计Sosei RMF1与合作伙伴将向新公司投入初期资金1,100万美元 以色列海法及东京, Dec. 21, 2016 (GLOBE...
-
Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
Pluristem and Sosei CVC will establish a new corporation which will pursue the clinical development and commercialization of PLX-PAD in JapanThe first indication to be developed will be Critical Limb...
-
《21世纪药物法案》旨在通过加速监管批准流程促进药物开发Pluristem的CLI计划已于欧洲及日本通过快速通道得以落实，上述两地均已通过了类似于《21世纪药物法案》的立法 以色列海法, Dec. 19, 2016 (GLOBE NEWSWIRE) -- 领先的胎盘细胞治疗产品开发商Pluristem Therapeutics Inc....